BIOTON S.A. (BIO.WA)
PLN 2.98
(-0.83%)
PLN 2.98
(-0.83%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 2.27 Million PLN | 60.1% |
| 2022 | 1.42 Million PLN | -50.69% |
| 2021 | 2.88 Million PLN | -91.5% |
| 2020 | 33.92 Million PLN | 126.77% |
| 2019 | -126.69 Million PLN | -582.35% |
| 2018 | 26.26 Million PLN | 461.49% |
| 2017 | -7.26 Million PLN | 74.57% |
| 2016 | -28.56 Million PLN | 94.54% |
| 2015 | -522.85 Million PLN | -14315.74% |
| 2014 | 3.67 Million PLN | 157.09% |
| 2013 | -6.44 Million PLN | -117.03% |
| 2012 | 37.83 Million PLN | 145.08% |
| 2011 | -83.93 Million PLN | -175.81% |
| 2010 | 110.72 Million PLN | 118.46% |
| 2009 | -599.87 Million PLN | -168.96% |
| 2008 | -223.03 Million PLN | -939.35% |
| 2007 | 26.57 Million PLN | -71.33% |
| 2006 | 92.69 Million PLN | 167.7% |
| 2005 | 34.62 Million PLN | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.79 Million PLN | 44.57% |
| 2024 Q1 | -5.03 Million PLN | -193.3% |
| 2023 Q3 | -4.41 Million PLN | -410.26% |
| 2023 Q2 | 1.42 Million PLN | 1161.94% |
| 2023 Q1 | -134 Thousand PLN | -102.67% |
| 2023 FY | 2.27 Million PLN | 60.1% |
| 2023 Q4 | 5.4 Million PLN | 222.33% |
| 2022 Q2 | 1.46 Million PLN | 146.73% |
| 2022 Q3 | -1.93 Million PLN | -232.1% |
| 2022 Q4 | 5.02 Million PLN | 359.77% |
| 2022 FY | 1.42 Million PLN | -50.69% |
| 2022 Q1 | -3.13 Million PLN | -849.39% |
| 2021 FY | 2.88 Million PLN | -91.5% |
| 2021 Q1 | -5.06 Million PLN | -127.07% |
| 2021 Q4 | -330 Thousand PLN | -107.15% |
| 2021 Q2 | 3.66 Million PLN | 172.36% |
| 2021 Q3 | 4.61 Million PLN | 25.83% |
| 2020 Q4 | 18.71 Million PLN | 681.99% |
| 2020 FY | 33.92 Million PLN | 126.77% |
| 2020 Q1 | 5.98 Million PLN | 115.4% |
| 2020 Q2 | 6.83 Million PLN | 14.14% |
| 2020 Q3 | 2.39 Million PLN | -64.96% |
| 2019 Q1 | 27.03 Million PLN | 168.03% |
| 2019 Q2 | -87.49 Million PLN | -423.62% |
| 2019 Q3 | -7.33 Million PLN | 91.61% |
| 2019 Q4 | -38.86 Million PLN | -429.67% |
| 2019 FY | -126.69 Million PLN | -582.35% |
| 2018 Q3 | -2.29 Million PLN | -103.47% |
| 2018 Q1 | 2.18 Million PLN | -59.66% |
| 2018 FY | 26.26 Million PLN | 461.49% |
| 2018 Q2 | 66.26 Million PLN | 2927.04% |
| 2018 Q4 | -39.73 Million PLN | -1629.95% |
| 2017 Q4 | 5.42 Million PLN | 469.69% |
| 2017 FY | -7.26 Million PLN | 74.57% |
| 2017 Q3 | -1.46 Million PLN | -226.95% |
| 2017 Q2 | -449 Thousand PLN | 95.83% |
| 2017 Q1 | -10.77 Million PLN | 52.52% |
| 2016 Q4 | -22.69 Million PLN | -694.43% |
| 2016 FY | -28.56 Million PLN | 94.54% |
| 2016 Q1 | 1.26 Million PLN | 100.24% |
| 2016 Q2 | -4.27 Million PLN | -438.18% |
| 2016 Q3 | -2.85 Million PLN | 33.22% |
| 2015 FY | -522.85 Million PLN | -14315.74% |
| 2015 Q4 | -531.65 Million PLN | -6755.65% |
| 2015 Q3 | 7.98 Million PLN | 921.81% |
| 2015 Q2 | -972 Thousand PLN | -154.55% |
| 2015 Q1 | 1.78 Million PLN | 197.0% |
| 2014 FY | 3.67 Million PLN | 157.09% |
| 2014 Q3 | 2.26 Million PLN | -61.41% |
| 2014 Q2 | 5.86 Million PLN | 216.11% |
| 2014 Q4 | 600 Thousand PLN | -73.5% |
| 2014 Q1 | -5.05 Million PLN | 10.61% |
| 2013 FY | -6.44 Million PLN | -117.03% |
| 2013 Q4 | -5.65 Million PLN | -311.73% |
| 2013 Q2 | 1.14 Million PLN | 303.19% |
| 2013 Q1 | -565 Thousand PLN | 96.25% |
| 2013 Q3 | -1.37 Million PLN | -219.6% |
| 2012 Q2 | 13.73 Million PLN | -73.81% |
| 2012 Q1 | 52.44 Million PLN | 190.2% |
| 2012 FY | 37.83 Million PLN | 145.08% |
| 2012 Q3 | -13.27 Million PLN | -196.67% |
| 2012 Q4 | -15.06 Million PLN | -13.45% |
| 2011 Q3 | 11.09 Million PLN | 158.26% |
| 2011 FY | -83.93 Million PLN | -175.81% |
| 2011 Q1 | -17.29 Million PLN | -117.04% |
| 2011 Q2 | -19.04 Million PLN | -10.14% |
| 2011 Q4 | -58.14 Million PLN | -624.02% |
| 2010 Q1 | -22.92 Million PLN | 95.75% |
| 2010 Q3 | -10.96 Million PLN | -124.06% |
| 2010 FY | 110.72 Million PLN | 118.46% |
| 2010 Q4 | 101.44 Million PLN | 1025.11% |
| 2010 Q2 | 45.56 Million PLN | 298.78% |
| 2009 Q3 | -13.38 Million PLN | 49.6% |
| 2009 Q4 | -538.96 Million PLN | -3926.03% |
| 2009 Q2 | -26.56 Million PLN | -26.68% |
| 2009 Q1 | -20.96 Million PLN | 0.0% |
| 2009 FY | -599.87 Million PLN | -168.96% |
| 2008 FY | -223.03 Million PLN | -939.35% |
| 2007 FY | 26.57 Million PLN | -71.33% |
| 2006 FY | 92.69 Million PLN | 167.7% |
| 2005 FY | 34.62 Million PLN | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioceltix S.A. | -13.68 Million PLN | 116.621% |
| Captor Therapeutics Spolka Akcyjna | -70.58 Million PLN | 103.223% |
| Mabion S.A. | 41.26 Million PLN | 94.487% |
| Molecure S.A. | -18.3 Million PLN | 112.426% |
| NanoGroup S.A. | -7.88 Million PLN | 128.835% |
| Pharmena S.A. | 28.94 Million PLN | 92.139% |
| Poltreg S.A. | -13.55 Million PLN | 116.788% |
| Pure Biologics Spólka Akcyjna | -35.69 Million PLN | 106.374% |
| Ryvu Therapeutics S.A. | -92.11 Million PLN | 102.47% |
| Synthaverse S.A. | 4.75 Million PLN | 52.186% |
| Urteste S.A. | -5.58 Million PLN | 140.727% |